TY - JOUR
T1 - Differences in COVID-19 Outcomes among Patients with Type 1 Diabetes
T2 - First vs Later Surges
AU - Gallagher, Mary Pat
AU - Rompicherla, Saketh
AU - Ebekozien, Osagie
AU - Wilkes, Meredith
AU - Antal, Zoltan
AU - Feuer, Alexis Jamie
AU - Rioles, Nicole
AU - Noor, Nudrat
AU - Gabriel, Liana
AU - O’Malley, Grenye
AU - Golden, Lauren
AU - Alonso, G. Todd
AU - Ospelt, Emma
AU - Odugbesan, Ori
AU - Lyons, Sarah K.
AU - Mungmode, Ann
AU - Prahalad, Priya
AU - Clements, Mark
AU - Neyman, Anna
AU - Demeterco-Berggren, Carla
AU - Rapaport, Robert
N1 - Funding Information:
Corresponding author: Osagie Ebekozien, MD, MPH, 11 Avenue de Lafayette, Boston, MA 02111; oebekozien@t1dexchange.org Disclosures: Dr Ebekozien reports receiving research grants from Medtronic Diabetes, Eli Lilly, and Dexcom, and receiving honoraria from Medtronic Diabetes.
Publisher Copyright:
© 2022 Turner White Communications Inc.. All rights reserved.
PY - 2022/1
Y1 - 2022/1
N2 - Background: Patient outcomes of COVID-19 have improved throughout the pandemic. However, because it is not known whether outcomes of COVID-19 in the type 1 diabetes (T1D) population improved over time, we investigated differences in COVID-19 outcomes for patients with T1D in the United States. Methods: We analyzed data collected via a registry of patients with T1D and COVID-19 from 56 sites between April 2020 and January 2021. We grouped cases into first surge (April 9, 2020, to July 31, 2020, n = 188) and late surge (August 1, 2020, to January 31, 2021, n = 410), and then compared outcomes between both groups using descriptive statistics and logistic regression models. Results: Adverse outcomes were more frequent during the first surge, including diabetic ketoacidosis (32% vs 15%, P< .001), severe hypoglycemia (4% vs 1%, P= .04), and hospitalization (52% vs 22%, P< .001). Patients in the first surge were older (28 [SD,18.8] years vs 18.0 [SD, 11.1] years, P< .001), had higher median hemoglobin A1c levels (9.3 [interquartile range {IQR}, 4.0] vs 8.4 (IQR, 2.8), P< .001), and were more likely to use public insurance (107 [57%] vs 154 [38%], P< .001). The odds of hospitalization for adults in the first surge were 5 times higher compared to the late surge (odds ratio, 5.01; 95% CI, 2.11-12.63). Conclusion: Patients with T1D who presented with COVID-19 during the first surge had a higher proportion of adverse outcomes than those who presented in a later surge.
AB - Background: Patient outcomes of COVID-19 have improved throughout the pandemic. However, because it is not known whether outcomes of COVID-19 in the type 1 diabetes (T1D) population improved over time, we investigated differences in COVID-19 outcomes for patients with T1D in the United States. Methods: We analyzed data collected via a registry of patients with T1D and COVID-19 from 56 sites between April 2020 and January 2021. We grouped cases into first surge (April 9, 2020, to July 31, 2020, n = 188) and late surge (August 1, 2020, to January 31, 2021, n = 410), and then compared outcomes between both groups using descriptive statistics and logistic regression models. Results: Adverse outcomes were more frequent during the first surge, including diabetic ketoacidosis (32% vs 15%, P< .001), severe hypoglycemia (4% vs 1%, P= .04), and hospitalization (52% vs 22%, P< .001). Patients in the first surge were older (28 [SD,18.8] years vs 18.0 [SD, 11.1] years, P< .001), had higher median hemoglobin A1c levels (9.3 [interquartile range {IQR}, 4.0] vs 8.4 (IQR, 2.8), P< .001), and were more likely to use public insurance (107 [57%] vs 154 [38%], P< .001). The odds of hospitalization for adults in the first surge were 5 times higher compared to the late surge (odds ratio, 5.01; 95% CI, 2.11-12.63). Conclusion: Patients with T1D who presented with COVID-19 during the first surge had a higher proportion of adverse outcomes than those who presented in a later surge.
KW - TD1
KW - diabetic ketoacidosis
KW - hypoglycemia
UR - http://www.scopus.com/inward/record.url?scp=85131638092&partnerID=8YFLogxK
U2 - 10.12788/JCOM.0084
DO - 10.12788/JCOM.0084
M3 - Article
AN - SCOPUS:85131638092
VL - 29
SP - 27
EP - 31
JO - Journal of Clinical Outcomes Management
JF - Journal of Clinical Outcomes Management
SN - 1079-6533
IS - 1
ER -